Idiopathic Pulmonary Fibrosis Clinical Trial
Official title:
A Comparative Assessment of Measurements Made in an Incremental Shuttle Walk Test and Incremental Cycle Ergometry Test in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic and potentially fatal lung disease. As IPF
progresses, patients become increasingly breathless with reduced exercise capacity and
quality of life. A cardiopulmonary exercise test (CPET) is a gold standard way of assessing
patients with IPF.
An incremental shuttle walk test is simpler, cheaper, more widely available and anecdotally
preferable to CPET. The investigators will compare the measurements made in an ISWT and a
CPET in patients with IPF . We aim to determine whether sufficient information can be
gathered in an ISWT to negate the need to undertake CPET.
Idiopathic pulmonary fibrosis (IPF) is a chronic and potentially fatal lung disease. As IPF
progresses, patients become increasingly breathless with reduced exercise capacity and
quality of life. Average life expectancy is three years from diagnosis but IPF progresses at
different rates in different people. In 2012 the British Lung Foundation estimated that
32,500 in the UK had IPF.
An accurate prognosis can help determine the most appropriate individual treatment option and
allow patients and their families to make suitable plans. Currently, measurements from
resting lung function tests are used to predict prognosis. However, measurement made during
CPET are more sensitive survival predictors and CPET is the gold standard test to assess
prognosis in IPF. A CPET test is relatively time-consuming and requires specialist equipment
that is not universally available. CPET is not routinely used in clinical practice for the
assessment of IPF.
The incremental shuttle walk test (ISWT) is quicker, cheaper and more widely available than
CPET. This study builds on previous research done by the Respiratory team which showed a
linear relationship between the distance walked in an ISWT and peak oxygen consumption during
a CPET, a useful prognostic predictor, in patients with interstitial lung disease. 40-50
patients with IPF will be recruited and will undertake both ISWT and CPET at University
Hospital, Coventry. The investigators will compare the results in the current cohort to those
of the previous study.
Additionally, the research team will compare oxygen pressure in capillary blood at the end of
an ISWT and a CPET. The investigators will also compare patient experience of the two tests
using questionnaires. This study paves the way for a simple, standardised test to more
accurately predict prognosis in IPF.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05984992 -
The First-in-human Study of SRN-001 in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT04312594 -
Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT03865927 -
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Completed |
NCT03979430 -
Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study
|
N/A | |
Enrolling by invitation |
NCT04905693 -
Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 3 | |
Terminated |
NCT04419558 -
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 3 | |
Completed |
NCT03725852 -
A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
Terminated |
NCT03573505 -
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT04148157 -
Quality of Life in IPF - Patient and Physician Perceptions
|
||
Active, not recruiting |
NCT03222648 -
Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis
|
N/A | |
Completed |
NCT02268981 -
Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF)
|
N/A | |
Completed |
NCT02257177 -
RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01524068 -
A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
|
Phase 2 | |
Enrolling by invitation |
NCT01382368 -
Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients
|
Phase 4 | |
Completed |
NCT01199887 -
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
Completed |
NCT01110694 -
Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
|
||
Active, not recruiting |
NCT02951416 -
Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
|
||
Terminated |
NCT00981747 -
Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis
|
Phase 2/Phase 3 | |
Completed |
NCT00540475 -
Pennsylvania Idiopathic Pulmonary Fibrosis Research Registry
|
||
Completed |
NCT00532233 -
SD, IL-13 Production Rate in IPF
|
Phase 2 |